Approaches to preventative and therapeutic HIV vaccines

Current Opinion in Virology

Volumn 17, Issue , 2016, Pages 104-109

  Gray, Glenda E ^a,b   Laher, Fatima ^a   Lazarus, Erica ^a   Ensoli, Barbara ^c   Corey, Lawrence ^d,e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d USA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; ERDOSTEINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS VECTOR; DNA VACCINE; MONOCLONAL ANTIBODY; TRANSACTIVATOR PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLADISTICS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE INSERTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN ADENOVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS LOAD; GENE VECTOR; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; PASSIVE IMMUNIZATION; VACCINATION; VIROLOGY;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HIV; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, DNA; VIRAL LOAD;

EID: 84962295972     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.02.010     Document Type: Review

References (42)

1. N.M. Flynn, D.N. Forthal, C.D. Harro, F.N. Judson, K.H. Mayer, and M.F. Para Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J Infect Dis 191 2005 654 665
2. P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J.W. Tappero, and K. Choopanya Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand J Infect Dis 194 2006 1661 1671
3. J.R. Mascola, S.W. Snyder, O.S. Weislow, S.M. Belay, R.B. Belshe, D.H. Schwartz, M.L. Clements, R. Dolin, B.S. Graham, G.J. Gorse, and et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group J Infect Dis 173 1996 340 348
4. B.F. Haynes, L. Verkoczy, and G. Kelsoe Redemption of autoreactive B cells Proc Natl Acad Sci U S A 111 2014 9022 9023
5. P.B. Gilbert, M.L. Peterson, D. Follmann, M.G. Hudgens, D.P. Francis, M. Gurwith, W.L. Heyward, D.V. Jobes, V. Popovic, S.G. Self, and et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial J Infect Dis 191 2005 666 677
6. M. Tongo, and W.A. Burgers Challenges in the design of a T cell vaccine in the context of HIV-1 diversity Viruses 6 2014 3968 3990
7. A. Duerr, Y. Huang, S. Buchbinder, R.W. Coombs, J. Sanchez, C. del Rio, M. Casapia, S. Santiago, P. Gilbert, L. Corey, and et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) J Infect Dis 206 2012 258 266
8. G.E. Gray, M. Allen, Z. Moodie, G. Churchyard, L.G. Bekker, M. Nchabeleng, K. Mlisana, B. Metch, G. de Bruyn, M.H. Latka, and et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study Lancet Infect Dis 11 2011 507 515
9. Z. Moodie, B. Metch, L.G. Bekker, G. Churchyard, M. Nchabeleng, K. Mlisana, F. Laher, S. Roux, K. Mngadi, C. Innes, and et al. Continued follow-up of phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated men PLoS One 10 2015 e0137666
10. G.E. Gray, Z. Moodie, B. Metch, P.B. Gilbert, L.G. Bekker, G. Churchyard, M. Nchabeleng, K. Mlisana, F. Laher, S. Roux, and et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study Lancet Infect Dis 14 2014 388 396
11. F. Li, A.C. Finnefrock, S.A. Dubey, B.T. Korber, J. Szinger, S. Cole, M.J. McElrath, J.W. Shiver, D.R. Casimiro, L. Corey, and et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study PLoS One 6 2011 e20479
12. N.L. Letvin, S.S. Rao, D.C. Montefiori, M.S. Seaman, Y. Sun, S.Y. Lim, W.W. Yeh, M. Asmal, R.S. Gelman, L. Shen, and et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys Sci Transl Med 3 2011 81ra36
13. G.J. Churchyard, C. Morgan, E. Adams, J. Hural, B.S. Graham, Z. Moodie, D. Grove, G. Gray, L.G. Bekker, M.J. McElrath, and et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) PLoS One 6 2011 e21225
14. S.M. Hammer, M.E. Sobieszczyk, H. Janes, S.T. Karuna, M.J. Mulligan, D. Grove, B.A. Koblin, S.P. Buchbinder, M.C. Keefer, G.D. Tomaras, and et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine N Engl J Med 369 2013 2083 2092
15. W.B. Williams, H.X. Liao, M.A. Moody, T.B. Kepler, S.M. Alam, F. Gao, K. Wiehe, A.M. Trama, K. Jones, R. Zhang, and et al. HIV-1 Vaccines. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies Science 349 2015 aab1253
16. M. Roederer, B.F. Keele, S.D. Schmidt, R.D. Mason, H.C. Welles, W. Fischer, C. Labranche, K.E. Foulds, M.K. Louder, Z.Y. Yang, and et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV Nature 505 2014 502 508
17. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, and et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N Engl J Med 361 2009 2209 2220
18. M.J. McElrath, S.C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D. Defawe, D.K. Carter, J. Hural, R. Akondy, and et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis Lancet 372 2008 1894 1905
19. S. Nitayaphan, P. Pitisuttithum, C. Karnasuta, C. Eamsila, M. de Souza, P. Morgan, V. Polonis, M. Benenson, T. VanCott, S. Ratto-Kim, and et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults J Infect Dis 190 2004 702 706
20. B.F. Haynes, P.B. Gilbert, M.J. McElrath, S. Zolla-Pazner, G.D. Tomaras, S.M. Alam, D.T. Evans, D.C. Montefiori, C. Karnasuta, R. Sutthent, and et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial N Engl J Med 366 2012 1275 1286
21. L. Corey, P.B. Gilbert, G.D. Tomaras, B.F. Haynes, G. Pantaleo, and A.S. Fauci Immune correlates of vaccine protection against HIV-1 acquisition Sci Transl Med 7 2015 310rv317
22. H.X. Liao, M. Bonsignori, S.M. Alam, J.S. McLellan, G.D. Tomaras, M.A. Moody, D.M. Kozink, K.K. Hwang, X. Chen, C.Y. Tsao, and et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2 Immunity 38 2013 176 186
23. G.E. Gray, E. Andersen-Nissen, N. Grunenberg, Y. Huang, S. Roux, F. Laher, C. Innes, N. Gu, C. DiazGranados, S. Phogat, and et al. HVTN 097: Evaluation of the RV144 vaccine regimen in HIV uninfected South African adults AIDS Res Hum Retroviruses 30SI 2014 A33 A34
24. J.D. Fuchs, P.A. Bart, N. Frahm, C. Morgan, P.B. Gilbert, N. Kochar, S.C. DeRosa, G.D. Tomaras, T.M. Wagner, L.R. Baden, and et al. Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals J AIDS Clin Res 6 2015
25. R.P. Ringe, A. Yasmeen, G. Ozorowski, E.P. Go, L.K. Pritchard, M. Guttman, T.A. Ketas, C.A. Cottrell, I.A. Wilson, R.W. Sanders, and et al. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers J Virol 89 2015 12189 12210
26. X. Wu, C. Wang, S. O'Dell, Y. Li, B.F. Keele, Z. Yang, H. Imamichi, N. Doria-Rose, J.A. Hoxie, M. Connors, and et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site J Virol 86 2012 5844 5856
27. J.E. Ledgerwood, E.E. Coates, G. Yamshchikov, J.G. Saunders, L. Holman, M.E. Enama, A. DeZure, R.M. Lynch, I. Gordon, S. Plummer, and et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clin Exp Immunol 182 2015 289 301
28. B. Ensoli, A. Cafaro, P. Monini, S. Marcotullio, and F. Ensoli Challenges in HIV vaccine research for treatment and prevention Front Immunol 5 2014 417
29. F. Garcia, A. Leon, J.M. Gatell, M. Plana, and T. Gallart Therapeutic vaccines against HIV infection Hum Vaccin Immunother 8 2012 569 581
30. A. Cafaro, A. Tripiciano, C. Sgadari, S. Bellino, O. Picconi, O. Longo, V. Francavilla, S. Butto, F. Titti, P. Monini, and et al. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine Expert Opin Biol Ther 15 Suppl. 1 2015 S13 S29
31. W.J. Krone, C. Debouck, L.G. Epstein, P. Heutink, R. Meloen, and J. Goudsmit Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo J Med Virol 26 1988 261 270
32. P. Reiss, A. de Ronde, J. Dekker, M. Aramideh, F. de Wolf, C. Debouck, J. Lange, and J. Goudsmit Seroconversion to HIV-1 rev- and tat-gene-encoded proteins AIDS 3 1989 105 106
33. B. Ensoli, V. Fiorelli, F. Ensoli, A. Cafaro, F. Titti, S. Butto, P. Monini, M. Magnani, A. Caputo, and E. Garaci Candidate HIV-1 Tat vaccine development: from basic science to clinical trials AIDS 20 2006 2245 2261
34. G. Rezza, V. Fiorelli, M. Dorrucci, M. Ciccozzi, A. Tripiciano, A. Scoglio, B. Collacchi, M. Ruiz-Alvarez, C. Giannetto, A. Caputo, and et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters J Infect Dis 191 2005 1321 1324
35. S. Bellino, A. Tripiciano, O. Picconi, V. Francavilla, O. Longo, C. Sgadari, G. Paniccia, A. Arancio, G. Angarano, N. Ladisa, and et al. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study Retrovirology 11 2014 49
36. S. Bellino, V. Francavilla, O. Longo, A. Tripiciano, G. Paniccia, A. Arancio, V. Fiorelli, A. Scoglio, B. Collacchi, M. Campagna, and et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate Rev Recent Clin Trials 4 2009 195 204
37. B. Ensoli, V. Fiorelli, F. Ensoli, A. Lazzarin, R. Visintini, P. Narciso, A. Di Carlo, A. Tripiciano, O. Longo, S. Bellino, and et al. The preventive phase I trial with the HIV-1 Tat-based vaccine Vaccine 28 2009 371 378
38. O. Longo, A. Tripiciano, V. Fiorelli, S. Bellino, A. Scoglio, B. Collacchi, M.J. Alvarez, V. Francavilla, A. Arancio, G. Paniccia, and et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up Vaccine 27 2009 3306 3312
39. B. Ensoli, S. Bellino, A. Tripiciano, O. Longo, V. Francavilla, S. Marcotullio, A. Cafaro, O. Picconi, G. Paniccia, A. Scoglio, and et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART PLoS One 5 2010 e13540
40. F. Ensoli, A. Cafaro, A. Casabianca, A. Tripiciano, S. Bellino, O. Longo, V. Francavilla, O. Picconi, C. Sgadari, S. Moretti, and et al. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial Retrovirology 12 2015 33
41. M. Caskey, F. Klein, J.C. Lorenzi, M.S. Seaman, A.P. West Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J.F. Scheid, and et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 Nature 522 2015 487 491
42. R.M. Lynch, E. Boritz, E.E. Coates, A. DeZure, P. Madden, P. Costner, M.E. Enama, S. Plummer, L. Holman, C.S. Hendel, and et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection Sci Transl Med 7 2015 319ra206